Simplify Logo
Otsuka Pharmaceutical

Otsuka Pharmaceutical

Global pharma maker of Abilify

Associate Director of Global Value Evidence Strategy

Full-Time
$169.2k - $253k/yr

+ Incentive opportunity

Junior, Mid
Master's, PhD
Remote in USA
Remote

Approximately 10% travel is required, including possible international travel.

About the job

Requirements
  • A PhD or Master’s degree in Health Economics, Outcomes Research, Health Services Research, Public Health, or a related discipline, with at least two years of related work experience for PhD/MD holders or four years for Master’s degree holders.
  • Experience in outcomes research, including dossier submissions for reimbursement and the design and development of pharmacoeconomic models.
  • Experience working with consumers of outcomes information.
  • Knowledge of epidemiology, economics, psychometrics, and medical writing.
  • Strong expertise in non-interventional study designs and methodological considerations in the statistical analyses of those research designs.
  • Strong understanding of the application and limitations of administrative claims data, electronic medical records data, hospital inpatient data, and patient- or physician-reported survey data.
  • Ability to independently develop research hypotheses, study protocols, and statistical analysis plans.
  • Working knowledge of customer or payer tool development and value dossiers.
  • Experience working with and overseeing external contractors and vendors.
  • Strong understanding of health systems around the world.
  • Excellent communication and presentation skills, problem-solving abilities, and interpersonal skills.
Responsibilities
  • Support the development and execution of global value evidence strategies by gathering, synthesizing, and analyzing evidence needs across payers, including health technology assessment authorities, providers, patients, and policymakers, to inform market access and value demonstration initiatives.
  • Participate in and demonstrate readiness to eventually lead the Value-Evidence Sub-Committee for assigned products and indications.
  • Participate in the development and maintenance of product- and indication-specific Integrated Evidence Plans.
  • Design and implement global health economics and outcomes research studies that support clinical, economic, and patient-centered value propositions and reimbursement requirements for Otsuka products and therapeutic areas of interest.
  • Implement evidence-generation research studies by collaborating with internal Otsuka programmers and data analysts or external vendors and academic institutions.
  • Support publication planning and execution by coordinating with publication teams and Otsuka Scientific Communications personnel.
  • Support preparation of medical or payer advisory meetings to solicit feedback on Otsuka products and therapeutic-area-specific disease impacts.
  • Identify and support projects that directly support the economic strategy for Otsuka products.
  • Evaluate the health economic, outcomes, and quality-related value of products and therapies versus other therapies or interventions using data from clinical trials and epidemiologic studies or real-world evidence, and produce data and tools.
  • Work with payers and other appropriate organizations to uncover evidence needs and develop economic tools and models for those audiences.
  • Assist in or develop product dossiers and other projects supporting different aspects of formulary submissions.
  • Identify external stakeholders’ needs and develop a collaborative research agenda with key stakeholders.
Desired Qualifications
  • Experience working in evidence-generation and value-demonstration initiatives for next-generation therapeutics treating psychiatric and neurological disorders.

About the company

Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.